Related Experiment Video

Updated: Jun 4, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Pneumococcal pneumonia in the era of heptavalent pneumococcal conjugate vaccine]

Antoni Payeras1, Aroa Villoslada, Margarita Garau

  • 1Servicio de Medicina Interna, Hospital Son Llàtzer, Red Española de Investigación en Patología Infecciosa (REIPI), Palma de Mallorca, Islas Baleares, España. apayeras@hsll.es

Enfermedades Infecciosas Y Microbiologia Clinica
|February 24, 2011
PubMed

Insights

Pneumococcal pneumonia after the pneumococcal conjugate vaccine (PCV-7) is primarily caused by non-vaccine serotypes. Younger, otherwise healthy patients face higher risks of severe complications and mortality from this infection.

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Clinical Microbiology

Background:

  • The introduction of the heptavalent pneumococcal conjugate vaccine (PCV-7) aimed to reduce pneumococcal pneumonia incidence.
  • Post-vaccine surveillance is crucial to understand evolving epidemiology, including serotype distribution and antibiotic resistance patterns.

Purpose of the Study:

  • To characterize clinical presentations, complications, serotypes, and antibiotic resistance of pneumococcal pneumonia following the widespread use of PCV-7 in pediatric vaccination programs.
  • To identify risk factors associated with severe outcomes like bacteremia, empyema, septic shock, and mortality.

Main Methods:

  • A prospective study was conducted on patients with culture-confirmed pneumococcal pneumonia treated in an emergency department between January 2006 and February 2010.
  • Data collected included patient demographics, clinical features, microbiological findings (serotyping, antibiotic susceptibility), and treatment outcomes.

Main Results:

  • The study analyzed 346 episodes (335 in adults). Community-acquired pneumonia accounted for 68.5% of cases.
  • Bacteremia occurred in 37.6% of patients, with higher risk in those under 65. Empyema (3.8%) and septic shock (9.5%) were significant complications.
  • Multivariate analysis linked bacteremia to positive urinary antigen tests and pleural effusion. Septic shock was associated with advanced disease stage, younger age, and pleural effusion. Mortality increased with complications, particularly septic shock.
  • Predominant serotypes identified were not covered by the PCV-7 vaccine.

Conclusions:

  • Pneumococcal pneumonia post-PCV-7 generalization is largely driven by non-vaccine serotypes.
  • Younger patients without underlying respiratory conditions exhibit an elevated risk for bacteremia, empyema, and septic shock.
  • Septic shock represents a critical complication associated with increased mortality in pneumococcal pneumonia.
Abstract

More Related Videos

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/4306:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: